) The Molecular and Cellular Oncology Program (MCOP) represents a new program resulting from a fusion of the previous Molecular Oncology and Cell Biology Programs. The new program brings together the leading molecular and cellular oncologists at the University of Pittsburgh School of Medicine, the Department of Biological Sciences at the University of Pittsburgh, and Carnegie Mellon University (CMU). The overall objective of the MCOP is to explore the mechanisms underlying the onset and progression of human neoplasia at the molecular level linked to studies of the functional input of molecular changes on cellular processes. The Program membership is comprised of a multi-disciplinary group of molecular biologists, cell biologists, biochemists, geneticists and clinical researchers who study the fundamental aspects of cell cycle regulation, signal transduction, gene transcription, genomic alterations and cell biology in both solid tumor and hematopoietic malignancies. The Program is led by Interim Directors, Paul D. Robbins, Ph.D., an Associate Professor in the Department of Molecular Genetics and Biochemistry, and Donald B. DeFranco, a Professor in the Departments of Biological Sciences, Neuroscience and Pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-12
Application #
6212108
Study Section
Subcommittee G - Education (NCI)
Project Start
1988-08-01
Project End
2004-07-30
Budget Start
Budget End
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications